Post sponsored by

MIL OSI Translation. Region: Germany / Deutschland –

Source: Bayer acquisition strengthens Bayer cell and gene therapy platform with the potential to provide urgently needed treatments for a wide range of diseases to patients with high unmet medical needs / AskBio’s leading AAV-based gene therapy platform already has both commercial and clinical trial therapy candidates Potential to help larger patient populations / Portfolio includes pre-clinical and clinical therapy candidates for the treatment of neuromuscular, cardiovascular and metabolic diseases as well as therapeutics for Pompe’s and Parkinson’s diseases, congestive heart failure as well as licensed clinical candidates for hemophilia and Duchenne disease. Muscular dystrophy / acquisition secures additional revenue-generating contract development and manufacturing business based on a highly efficient Pro10 ™ cell line / AskBio will continue as an independent company / Prepaid purchase price of $ 2 billion and up to $ 2 billion in performance milestone payments


EDITOR’S NOTE: This article is a translation. Apologies should the grammar and / or sentence structure not be perfect.

MIL Translation OSI